NCT05184062 - A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults | Biotech Hunter

Enrollment

272

Participants

Timeline

Start Date

December 3, 2021

Primary Completion Date

August 15, 2022

Study Completion Date

May 6, 2023

Conditions

Coronavirus Disease 2019 (COVID-19)

Interventions

DRUG

600 mg AZD7442 IV

Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.

DRUG

600mg placebo IV

Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.

Trial Locations (14)

Research Site, Beijing

Research Site, Shanghai

Research Site, Shanghai

Research Site, Shanghai

Research Site, Suzhou

Research Site, Xuzhou

Research Site, Hangzhou

Research Site, Fuzhou

Research Site, Chongqing

Research Site, Changsha

Research Site, Haikou

Research Site, Lanzhou

Research Site, Ürümqi

Research Site, Baoding